Solid Biosciences Inc. Operating Lease, Payments
Solid Biosciences Inc. (SLDB) reported Operating Lease, Payments of $4.18 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-19
- Solid Biosciences Inc. operating lease, payments for the quarter ending 2019-09-30 was $590.00K.
- Solid Biosciences Inc. operating lease, payments for the quarter ending 2019-06-30 was $318.00K.
- Solid Biosciences Inc. operating lease, payments for the quarter ending 2019-03-31 was $787.00K.
- Solid Biosciences Inc. operating lease, payments for fiscal 2025 was $4.18M, a 2.06% decline from fiscal 2024.
- Solid Biosciences Inc. operating lease, payments for fiscal 2024 was $4.26M, a 5.27% decline from fiscal 2023.
- Solid Biosciences Inc. operating lease, payments for fiscal 2023 was $4.50M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.18M 10-K · filed 2026-03-19 | |||
| 2024-12-31 | $4.26M 10-K · filed 2026-03-19 | |||
| 2023-12-31 | $4.50M 10-K · filed 2025-03-06 | |||
| 2019-09-30 | $590.00K 10-Q · filed 2019-11-12 | $908.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.70M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $318.00K 10-Q · filed 2019-08-14 | $1.10M 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $787.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |